These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058 [TBL] [Abstract][Full Text] [Related]
6. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173 [TBL] [Abstract][Full Text] [Related]
7. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Sjouke B; Langslet G; Ceska R; Nicholls SJ; Nissen SE; Öhlander M; Ladenson PW; Olsson AG; Hovingh GK; Kastelein JJ Lancet Diabetes Endocrinol; 2014 Jun; 2(6):455-63. PubMed ID: 24731671 [TBL] [Abstract][Full Text] [Related]
8. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687 [TBL] [Abstract][Full Text] [Related]
9. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Gelsinger C; Steinhagen-Thiessen E; Kassner U Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743 [TBL] [Abstract][Full Text] [Related]
11. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study). Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937 [TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839 [TBL] [Abstract][Full Text] [Related]
14. Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Patel N; Hegele RA Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601 [TBL] [Abstract][Full Text] [Related]
15. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Bell DA; Hooper AJ; Burnett JR Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756 [TBL] [Abstract][Full Text] [Related]
16. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Bell DA; Hooper AJ; Watts GF; Burnett JR Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021 [TBL] [Abstract][Full Text] [Related]
18. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. Vogt A; Parhofer KG Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485 [TBL] [Abstract][Full Text] [Related]
19. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Gouni-Berthold I; Berthold HK Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301 [TBL] [Abstract][Full Text] [Related]